Cambridge
Cambridge
Cambridge, England, United Kingdom16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | MASH With Fibrosis; NASH With Fibrosis | Recruiting | Phase 3 | 2026-10-06 | NCT06215716 | |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Active, not recruiting | Not applicable | 2026-09-30 | NCT05051033 | |
| WIRE - Novel Treatments in Renal Cell Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-09-25 | NCT03741426 | |
| A Study of Mosliciguat in PH-ILD | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hypertensive disorder, interstitial lung disease, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-09-10 | NCT06635850 | |
| Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, neoplasm | Recruiting | Phase 3 | 2026-09-01 | NCT02582697 | |
| A Study of Pitolisant in Patients With Prader-Willi Syndrome | Abnormalities, Multiple, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disorders of Excessive Somnolence, Dyssomnias, Imprinting Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Overweight, Prader-Willi syndrome, Sleep Disorders, Intrinsic, chromosomal disorder, hereditary disease, intellectual disability, nervous system disorder, nutritional disorder, obesity disorder, overnutrition, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-08-25 | NCT06366464 | |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, embryonal carcinoma, immature ovarian teratoma, malignant germ cell tumor, mesonephric neoplasm, neoplasm, teratoma, yolk sac tumor | Recruiting | Phase 3 | 2026-08-25 | NCT03067181 | |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-13 | NCT05671510 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 2 | 2026-06-03 | NCT04663204 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| Hearing and Structure Preservation Via ECochG | Ear Diseases, Hearing Loss, Sensorineural, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, nervous system disorder, otorhinolaryngologic disease | Recruiting | Not applicable | 2026-01-06 | NCT06268340 | |
| Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2025-12-11 | NCT03755791 | |
| GyroGlove Use in Essential Tremor Patients | central nervous system disorder, essential tremor, movement disorder, nervous system disorder | Not yet recruiting | Not applicable | 2025-03-14 | NCT05958030 | |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | COVID-19, Community-Acquired Infections, Community-Acquired Pneumonia, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2024-07-12 | NCT02735707 | |
| Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Ear Diseases, Neoplasms by Site, Ototoxicity, Pathologic Processes, Pathological Conditions, Signs and Symptoms, central nervous system cancer, injury, neoplasm, nervous system disorder, otorhinolaryngologic disease, radiation injury | Active, not recruiting | Not stated | 2013-09-20 | NCT00683319 |